Intel stock spikes after report of possible US government stake
Investing.com - Avadel Pharma (NASDAQ: AVDL) reported first quarter EPS of $-0.050, $0.03 worse than the analyst estimate of $-0.020. Revenue for the quarter came in at $50.41M versus the consensus estimate of $52.48M.
Guidance
Avadel Pharma sees FY 2025 revenue of $240.000M-$260.000M versus the analyst consensus of $250.300M.
Avadel Pharma’s stock price closed at $7.91. It is down -20.500% in the last 3 months and down -50.960% in the last 12 months.
Avadel Pharma saw 0 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Avadel Pharma’s stock price’s past reactions to earnings here.
According to InvestingPro, Avadel Pharma’s Financial Health score is "fair performance".
Check out Avadel Pharma’s recent earnings performance, and Avadel Pharma’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar